Profile: Ambit Biosciences is a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. Our compound AC220 is a small molecule kinase inhibitor for the treatment of acute myeloid leukemia, and a second clinical-stage compound AC480 is a panHER kinase inhibitor. Our AC220 binds potently and specifically to FLT3 with sub-nanomolar inhibition of FLT3 phosphorylation in an AML cell line derived from human patients.